<div id="readability-page-1"><p>Generali Asset Management SPA SGR lowered its holdings in  Eli Lilly and Company (NYSE:LLY - Free Report) by 9.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 61,292 shares of the company's stock after selling 6,430 shares during the quarter. Eli Lilly and Company comprises  1.0% of Generali Asset Management SPA SGR's investment portfolio, making the stock its 18th biggest holding. Generali Asset Management SPA SGR's holdings in Eli Lilly and Company were worth $46,766,000 as of its most recent SEC filing.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 12/29 - 01/02</li></ul><p>Other hedge funds and other institutional investors have also made changes to their positions in the company. Braun Bostich &amp; Associates Inc. increased its stake in  Eli Lilly and Company by 2.5% in the second quarter. Braun Bostich &amp; Associates Inc. now owns 527 shares of the company's stock valued at $411,000 after purchasing an additional 13 shares during the last quarter.  Rise Advisors LLC lifted its position in shares of  Eli Lilly and Company by 1.8% during the 2nd quarter. Rise Advisors LLC now owns 732 shares of the company's stock worth $571,000 after buying an additional 13 shares during the last quarter.  Occidental Asset Management LLC boosted its holdings in shares of  Eli Lilly and Company by 0.7% in the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company's stock valued at $1,533,000 after buying an additional 13 shares in the last quarter.  New Insight Wealth Advisors grew its position in shares of  Eli Lilly and Company by 3.4% in the 2nd quarter. New Insight Wealth Advisors now owns 394 shares of the company's stock valued at $307,000 after buying an additional 13 shares during the last quarter.  Finally, Dash Acquisitions Inc. raised its stake in  Eli Lilly and Company by 2.8% during the 2nd quarter. Dash Acquisitions Inc. now owns 485 shares of the company's stock worth $387,000 after acquiring an additional 13 shares in the last quarter. Institutional investors and hedge funds own  82.53% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>LLY has been the subject of several research analyst reports. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a &#34;hold&#34; rating in a research note on Tuesday, December 2nd. CICC Research upped their target price on Eli Lilly and Company from $801.00 to $1,060.00 and gave the company a &#34;neutral&#34; rating in a research report on Thursday, November 13th. Weiss Ratings  restated a &#34;buy (b-)&#34; rating on shares of Eli Lilly and Company in a research note on Monday, December 22nd. Wolfe Research boosted their price objective on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Wells Fargo &amp; Company increased their price objective on Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, December 10th. Five equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued  a Buy rating and five have assigned  a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Buy&#34; and an average target price of $1,155.36.</p><ul><li>FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026</li></ul><p><b>Read Our Latest Report on Eli Lilly and Company</b></p><h2>Eli Lilly and Company Stock Up 0.5%</h2><p>LLY opened at $1,079.83 on Friday. The business has a 50 day moving average price of $1,013.16 and a two-hundred day moving average price of $850.41. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. The company has a market cap of $1.02 trillion, a PE ratio of 52.83, a P/E/G ratio of 0.77 and a beta of 0.35. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,111.99. </p><ul><li>Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake</li></ul><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company's revenue was up 53.9% on a year-over-year basis. During the same period last year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.  As a group, research analysts anticipate that  Eli Lilly and Company will post 23.48 EPS for the current year. </p><h2>Eli Lilly and Company Increases Dividend</h2><p>The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 annualized dividend and a yield of 0.6%. This is an increase from Eli Lilly and Company's previous quarterly dividend of $1.50. Eli Lilly and Company's dividend payout ratio  is presently 29.35%. </p><h2>Eli Lilly and Company Company Profile</h2> (Free Report)<p>Eli Lilly and Company <span>NYSE: LLY<span></span></span> is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>Do not delete, read immediately</li><li>The $100 Trillion AI Story No One Is Telling You</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>But this $2 Gold Stock Before May 20, 2026</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Generali Asset Management SPA SGR has reduced its holdings in Eli Lilly and Company (NYSE: LLY) by 9.5% in Q3, now owning 61,292 shares valued at approximately $46.77 million. This stock represents 1.0% of their investment portfolio. Other institutional investors have also adjusted their positions, with various firms increasing their stakes. Analysts have set new price targets for Eli Lilly, with a consensus rating of "Buy" and an average target price of $1,155.36. The stock opened at $1,079.83, showing a slight increase of 0.5%.</p>

Generali Asset Management SPA SGR Decreases Holdings in Eli Lilly and Company $LLY